Drug Trial News

RSS

Targeted drug therapy shows promise for ulcerative colitis remission

An international placebo-controlled study led by Cedars-Sinai suggests that a targeted drug therapy that was developed by researchers at Cedars-Sinai is safe and effective at helping people with moderate to severe ulcerative colitis reach clinical remission.

26 Sep 2024

Study reveals life-changing impact of gene therapy for hemophilia B patients

Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy, according to the results of an international Phase III clinical trial published today in the New England Journal of Medicine by researchers from the University of Pennsylvania Perelman School of Medicine and a multicenter group of investigators.

25 Sep 2024

WHO issues new guidance to enhance clinical trials worldwide

The World Health Organization (WHO) today released guidance to improve the design, conduct and oversight of clinical trials in countries of all income levels.

25 Sep 2024

New approach to B-ALL treatment reduces side effects and enhances survival

Clinical trial results from St. Jude Children's Research Hospital demonstrate benefits to using genomics and early treatment response to guide risk classification of children with B-cell acute lymphoblastic leukemia (B-ALL).

24 Sep 2024

Semaglutide shows promise in treating chronic skin condition in obese patients

A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in treating hidradenitis suppurative (HS), a common and chronic skin condition, in people with obesity.

24 Sep 2024

Innovative ALS study receives $22 million grant for experimental drug

Mayo Clinic in Florida has received a grant from the National Institute of Neurological Disorders and Stroke (NIDS) to begin an innovative study that will provide hundreds of patients with amyotrophic lateral sclerosis (ALS) access to the experimental drug ibudilast over six months.

24 Sep 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis

The BLA submission for nipocalimab marks a significant advancement in treating generalized myasthenia gravis, showing improved MG-ADL scores in clinical trials.

From Johnson & Johnson 24 Sep 2024

New model identifies cancer patients at high risk for ER visits during clinical trials

Investigators from the SWOG Cancer Research Network have developed and validated a risk prediction model for identifying which patients with advanced cancer who are enrolled to clinical trials are at highest risk for unplanned emergency room (ER) visits and hospital stays.

23 Sep 2024

FORT-2 trial shows promising results for bladder cancer immunotherapy combination

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

19 Sep 2024

Adaptive platform trial tests multiple treatments for traumatic brain injury

Traumatic brain injury (TBI) results in close to 70,000 deaths in the United States every year, and it is the cause of long-term physical, cognitive and mental disability in 5 million Americans. But despite three decades of work, treatments are sorely lacking.

19 Sep 2024

Drug breakthrough provides new hope for cancer patients with cachexia

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and muscle wasting.

19 Sep 2024

Phase 1 trial shows safety and efficacy of personalized vaccine for lymphoplasmacytic lymphoma

A team of researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S., and The University of Texas M.D. Anderson Cancer Center, have reported safety and efficacy results from a Phase 1 trial that featured a personalized vaccine to treat lymphoplasmacytic lymphoma, a rare and slow-growing type of blood cancer, according to a study published recently in Nature Communications.

19 Sep 2024

Multiple myeloma drug shows efficacy in treating rare bleeding disorder

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

19 Sep 2024

Cancer drug shows promise for treating rare bleeding disorder

A clinical trial has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that impacts more than 1 in 5,000 people worldwide. The trial, led by Keith McCrae, M.D., of Cleveland Clinic and supported by the National Institutes of Health, was stopped early because of these successful findings, and has been published in the New England Journal of Medicine.

19 Sep 2024

Clinical trial finds pomalidomide effective for treating rare bleeding disorder

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT), a rare bleeding disorder that affects 1 in 5,000 people worldwide.

18 Sep 2024

Innovative triplet therapy shows encouraging results in advanced chronic myeloid leukemia

According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) – including both accelerated or myeloid blast phases of the disease – or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

17 Sep 2024

Ohio State's novel DHODH inhibitor enters first human trials

A new therapeutic agent discovered and developed at The Ohio State University will soon be used for cancer treatment at the patient's bedside as part of a clinical trial.

17 Sep 2024

Combination immunotherapy yields 10-year survival for metastatic melanoma patients

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to a new report from Weill Cornell Medicine and Dana-Farber Cancer Center investigators and their colleagues.

16 Sep 2024

High-dose vitamin D3 cannot be recommended as treatment for metastatic colon cancer

A double-blind randomized phase 3 clinical trial led by Dana-Farber Cancer Institute researchers and conducted across several hundred cancer centers in the U.S. tested the addition of high-dose vitamin D3 to standard treatment for patients with untreated metastatic colorectal cancer.

16 Sep 2024

Early data shows mRNA-4359 may benefit patients with advanced solid cancers

Interim data from the Phase I dose escalation part of the mRNA cancer immunotherapy (mRNA-4359), show promise in patients with advanced solid cancers.

16 Sep 2024